320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience

Background

Ovarian cancer is 3rd most common malignancy in Indian women and 8^th common cause of cancer related death in India. The aim for this study was to evaluate clinicopathological factors, patterns of treatment, progression free survival (PFS) and overall survival (OS) in Indian patients with advanced ovarian cancer.

Methods

This is a retrospective analysis of patients with stage III-IV ovarian cancer treated at HCG Cancer Center, Ahmedabad from June 2018- March 2023. Patients were identified using the institutional tumor registry and medical records and data was collected.

Results

Out of total 94 patients identified; 79 patients were eligible for further analysis. Median age was 55 years (range 29 to 76 years). 62 (78%) patients had stage III (IIIA-5,IIIB-3, IIIc-44) & 17 (22%) had stage IV (IVA-10, IVB-7). Most common histology was high grade serous carcinoma in 76 (96%) patients. Majority of patients received neoadjuvant chemotherapy followed by interim cytoreductive surgery (CRS), [61 patients (78%)] whereas 18 patients (22 %) underwent upfront surgery. Median duration of neoadjuvant chemotherapy was 3 months. 21 (26.57%) patients were treated with hyperthermic intraperitoneal chemotherapy (HIPEC). 60 patients (76%) received maintenance therapy [43 patients bevacizumab, 10 patients PARP (poly ADP ribose polymerase) inhibitor and 6 patients received both]. 33 patients (41%) developed recurrence among which 32 received further chemotherapy. In recurrent setting, patients received a median 3 lines of systemic therapy (range 0-5). Genetic testing was offered to all patients at the time of diagnosis, but only 36 (45%) patients opted for it. BRCA1 mutation was detected in 8 patients (22.2%), BRCA2 mutation in 4 (11%). Median follow up was 17 months. Median PFS was 20 months with 95% CI (16-22) & Median OS was not reached, 5-year OS was 32.1%.

Conclusions

Median PFS and OS in advanced ovarian cancer at our institute is comparable to global standards. With the availability of biosimilars and genetic testing, more patients are able to access maintenance therapies. Hopefully more patients can access standard of care therapies which will help close the gap between less developed and developed countries in terms of long term outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.